321 related articles for article (PubMed ID: 36564679)
1. The multifaceted role of MUC1 in tumor therapy resistance.
Jin W; Zhang M; Dong C; Huang L; Luo Q
Clin Exp Med; 2023 Sep; 23(5):1441-1474. PubMed ID: 36564679
[TBL] [Abstract][Full Text] [Related]
2. MUC1: a multifaceted oncoprotein with a key role in cancer progression.
Nath S; Mukherjee P
Trends Mol Med; 2014 Jun; 20(6):332-42. PubMed ID: 24667139
[TBL] [Abstract][Full Text] [Related]
3. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
4. MUC1 promotes cancer stemness and predicts poor prognosis in osteosarcoma.
Liu J; Xu Y; Xu T; Liu Y; Liu J; Chai J; Yang Y; Hu P; Li M; Jia Q; Zhang C
Pathol Res Pract; 2023 Feb; 242():154329. PubMed ID: 36680928
[TBL] [Abstract][Full Text] [Related]
5. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
6. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.
Chen W; Zhang Z; Zhang S; Zhu P; Ko JK; Yung KK
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207342
[TBL] [Abstract][Full Text] [Related]
7. Functional Expression of Mucin1 in Human Duodenal Adenocarcinoma.
Shiba S; Miki A; Ohzawa H; Teratani T; Sakuma Y; Lefor AK; Kitayama J; Sata N
J Surg Res; 2019 Jun; 238():79-89. PubMed ID: 30763811
[TBL] [Abstract][Full Text] [Related]
8. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
Li Q; Liu G; Shao D; Wang J; Yuan H; Chen T; Zhai R; Ni W; Tai G
Int J Biochem Cell Biol; 2015 Feb; 59():116-25. PubMed ID: 25526895
[TBL] [Abstract][Full Text] [Related]
9. MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer.
Gunda V; Souchek J; Abrego J; Shukla SK; Goode GD; Vernucci E; Dasgupta A; Chaika NV; King RJ; Li S; Wang S; Yu F; Bessho T; Lin C; Singh PK
Clin Cancer Res; 2017 Oct; 23(19):5881-5891. PubMed ID: 28720669
[No Abstract] [Full Text] [Related]
10. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
11. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
12. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
13. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.
Lau SK; Shields DJ; Murphy EA; Desgrosellier JS; Anand S; Huang M; Kato S; Lim ST; Weis SM; Stupack DG; Schlaepfer DD; Cheresh DA
PLoS One; 2012; 7(5):e36753. PubMed ID: 22586492
[TBL] [Abstract][Full Text] [Related]
14. Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer.
Li W; Han Y; Sun C; Li X; Zheng J; Che J; Yao X; Kufe D
Theranostics; 2022; 12(3):999-1011. PubMed ID: 35154471
[TBL] [Abstract][Full Text] [Related]
15. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis.
Zhao Q; Piyush T; Chen C; Hollingsworth MA; Hilkens J; Rhodes JM; Yu LG
Cell Death Dis; 2014 Oct; 5(10):e1438. PubMed ID: 25275599
[TBL] [Abstract][Full Text] [Related]
16. Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents.
Farahmand L; Merikhian P; Jalili N; Darvishi B; Majidzadeh-A K
Curr Cancer Drug Targets; 2018; 18(8):737-748. PubMed ID: 28669345
[TBL] [Abstract][Full Text] [Related]
17. Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells.
Hasegawa H; Komoda M; Yamada Y; Yonezawa S; Tsutsumida H; Nagai K; Atogami S; Tsuruda K; Osaka A; Sasaki D; Yanagihara K; Imaizumi Y; Tsukasaki K; Miyazaki Y; Kamihira S
Leuk Lymphoma; 2011 Jun; 52(6):1108-17. PubMed ID: 21599593
[TBL] [Abstract][Full Text] [Related]
18. Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration.
Cascio S; Farkas AM; Hughey RP; Finn OJ
Oncotarget; 2013 Oct; 4(10):1686-97. PubMed ID: 24072600
[TBL] [Abstract][Full Text] [Related]
19. Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression.
Hou R; Jiang L; Liu D; Lin B; Hu Z; Gao J; Zhang D; Zhang S; Iwamori M
Int J Mol Med; 2017 Aug; 40(2):293-302. PubMed ID: 28586014
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
Jing X; Liang H; Hao C; Yang X; Cui X
Oncol Rep; 2019 Feb; 41(2):801-810. PubMed ID: 30483806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
